display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced mGC or mGEJC
mGC or mGEJC - M - HER2 negativemGC or mGEJC - M - HER2 neg/PDL1 positive
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone JAVELIN Gastric 100 JAVELIN Gastric 100 ...

Study type: